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Better biomarkers are urgently needed to cancer detection, diagnosis, and prognosis. While the genomics community is making 
significant advances in understanding the molecular basis of disease, proteomics will delineate the functional units of a cell, pro-
teins and their intricate interaction network and signaling pathways for the underlying disease. Great progress has been made to 
characterize thousands of proteins qualitatively and quantitatively in complex biological systems by utilizing multi-dimensional 
sample fractionation strategies, mass spectrometry and protein microarrays. Comparative/quantitative analysis of high-quality 
clinical biospecimen (e.g., tissue and biofluids) of human cancer proteome landscape has the potential to reveal protein/peptide 
biomarkers responsible for this disease by means of their altered levels of expression, post-translational modifications as well as dif-
ferent forms of protein variants. Despite technological advances in proteomics, major hurdles still exist in every step of the bio-
marker development pipeline. The National Cancer Institute’s Clinical Proteomic Technologies for Cancer initiative (NCI-CPTC) has 
taken a critical step to close the gap between biomarker discovery and qualification by introducing a pre-clinical “verification” 
stage in the pipeline, partnering with clinical laboratory organizations to develop and implement common standards, and devel-
oping regulatory science documents with the US Food and Drug Administration to educate the proteomics community on analyti-
cal evaluation requirements for multiplex assays in order to ensure the safety and effectiveness of these tests for their intended use.
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INTRODUCTION
1. Advances in clinical proteomics research
In the post-genome era, the field of proteomics sparked 
great interest in the pursuit of protein/peptide biomarkers 
especially after mass spectrometry (MS) demonstrated the 
capability of characterizing a large number of proteins and 
their post-translational modifications (PTMs) in complex 
biological systems [1-12]. Technological advances in protein 
science such as protein/antibody chips, depletion of multi-
ple high abundance proteins by affinity columns, and affin-
ity enrichment of targeted protein analytes as well as multi-
dimensional chromatographic fractionation, all of which 
expanded the dynamic range of detection for low abun-
dance proteins by several orders of magnitude in serum or 
plasma, have made it possible for the detection of disease-
relevant proteins in these complex biological matrices [13-
21]. In fact, proteomics has been widely applied in various 
areas of science, ranging from the deciphering of molecular 
pathogenesis of diseases, the characterization of novel drug 
targets, to the discovery of potential diagnostic and prog-
nostic biomarkers, where the technology is able to identify 
and quantify proteins associated with a particular disease by 
means of their altered levels of expression [22-24] and/or 
PTMs [25-27] between the control and disease states (i.e., 
biomarker candidates). This type of comparative (semi-
quantitative) analysis enables correlations to be drawn be-
tween the range of proteins, their variations and modifica-
tions produced by a cell, tissue and biofluids and the initia-
tion, progression, therapeutic monitoring or remission of a 62     www.kjlm.org
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disease state. Post-translational modifications including 
phosphorylation, glycosylation, acetylation and oxidation, 
in particular, have been of great interest in this field as it has 
been demonstrated to be linked to disease pathology and 
useful targets for therapeutics. In addition to MS-based 
large-scale protein and peptide sequencing, other innova-
tive approaches including self-assembling protein microar-
rays [28] and bead-based flow cytometry [29] to identify 
and quantify proteins and protein-protein interaction in a 
high throughput manner have furthered our understanding 
in the molecular mechanisms involved in diseases. In sum-
mary, clinical proteomics has come a long way in the past 
decade in terms of technology/platform development, pro-
tein chemistry, and bioinformatics to identify molecular 
signatures of diseases based on protein pathways and sig-
naling cascades. Hence, it undoubtedly holds great promise 
for disease diagnosis, prognosis, and prediction of thera-
peutic outcome on an individualized basis. However, with-
out proper study design and implementation of robust ana-
lytical techniques, the efforts and expectations to make bio-
markers a useful reality in the near future can easily be 
hampered. This is clearly manifested by the stagnant rate of 
clearance or approval of protein biomarkers for all diseases 
by the Food and Drug Administration (FDA) in the US (i.e., 
averaging ~1.5 protein/yr in the past 15 yr [30]), in contrast 
to over 1,200 biomarker candidates reported in the scien-
tific literature for cancer alone. The question arises as to 
what has caused such a huge disconnect between biomarker 
discovery using modern proteomic technologies and bio-
marker qualification requiring much more stringent analyt-
ical and clinical criteria. Several major barriers have been 
postulated to be responsible for this discrepancy, including: 
(1) technological variability within/across proteomic plat-
forms; (2) improper biospecimen collection, handling, stor-
age and processing; (3) incapability of credentialing bio-
marker candidates prior to costly and time-consuming 
clinical qualification studies using well-established method-
ologies; (4) a lack of knowledge in the evaluation criteria re-
quired for these distinct processes in the pipeline and in 
regulatory science by the research community; (5) insuffi-
cient publicly available high-quality reagents and data sets 
to the cancer research community; (6) need for improved 
data analysis tools for the analysis, characterization, and 
comparison of large datasets and multi-dimensional data; 
and (6) a lack of proper experimental study design when 
performing studies involving clinical samples in biomarker 
studies (Fig. 1). If proteomics is to successfully make its way 
into clinical diagnostics, universally accepted metrics will 
be needed at many steps along the way to ensure that ob-
served changes are attributable to biological states, not 
workflow variability.
On the discovery front, semi-quantitative proteomic 
methodologies routinely used for biomarker research be-
tween normal and diseased states are differential two-di-
mensional gel electrophoresis (2DGE), comparative label-
free and labeling approaches (e.g., Isotope Coded Affinity 
Tags, iTRAQ, Stable Isotope Labeling with Amino Acids in 
Cell Culture) followed by liquid chromatography mass spec-
trometry (LC-MS). Although such comparative analysis 
yields insightful information on possible changes as a result 
of disease, these current methods in clinical proteomics 
based, for the most part, on MS and its combination with 
2DGE, chromatography or biobead technology have a con-
centration sensitivity level (CSL) not lower than 10 nM. This 
coupled to the use of blood as a biospecimen in discovery 
research (a commonly used biospecimen which is highly 
complex and has a wide dynamic range of protein concen-
trations), makes it is very difficult to discover (measure) low 
abundance proteins (potential biomarkers). One remedy to 
this problem is to develop and apply nanotechnology in 
clinical proteomics which can substantially enhance the CSL, 
as well as the throughput of analytical measurement systems 
while lowering their cost. Not only does nanotechnology 
have the potential of satisfying many criteria required for the 
advancement of clinical proteomics, essential changes in the 
physicochemical properties of substances on their conver-
sion to the nanostructured state have also made it possible to 
create efficient systems for drug delivery to targets. Cur-
rently, one of the most promising nanotechnological pro-
teomics being developed for medical research is biosensor-
based nanodiagnostics. An example of this is the develop-
ment of a magneto-nano sensor protein chip and a multiplex 
Fig. 1. Barriers between candidate biomarker discovery by proteomics and 
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magnetic sorter based on magnetic nanoparticles that allow 
rapid conversion of discrete biomolecules binding events 
into electrical signals, which can detect target molecules 
down to the single molecule level in less than an hour [31]. 
2. Issues and challenges in clinical proteomics
In reality, proteomics has not lived up to the hopes for 
identifying effective biomarkers in the past decade, due in 
part to the lack of coherent pipeline connecting biomarker 
discovery efforts with well-established methods for clinical 
qualification studies (commonly known as biomarker vali-
dation). As a result, among the critical challenges facing the 
proteomics community is the lack of an ability to accurately 
and reproducibly measure a meaningful number of proteins 
in biospecimens across institutions. Better understanding of 
the challenges and strategies inherent in each phase of the 
proteomics pipeline is required to both accelerate the pace 
and quality of biomarker development and facilitate the de-
livery and deployment of novel clinical tests. Indeed, chal-
lenges in proteomics encompass several stages of the bio-
marker development pipeline, including a lack of technology 
standardization/optimization; quality affinity reagents; ana-
lytical validation review documents for developers of multi-
plex proteomics assays; and proper experimental design 
when performing studies involving clinical samples (e.g., 
statistical power calculation on the number of biospecimens 
needed to ensure meaningful results, and biospecimen qual-
ity with proper representation of patient population).
DISCUSSION
1. Reconstructing the pipeline through verification
The conventional biomarker development pipeline in-
volves a discovery stage followed by a qualification stage 
(commonly known as biomarker validation) on large co-
horts (Fig. 2A), prior to clinical implementation. Tradition-
ally, the discovery stage is performed on a MS-based plat-
form for global unbiased sampling of the proteome, while 
biomarker qualification and clinical implementation gener-
ally involve the development of an antibody-based protocol, 
such as the widely used enzyme linked immunosorbent as-
says (ELISAs). Although this process has the potential to 
deliver clinically important biomarkers, it is not the most ef-
ficient as the latter is low-throughput, very costly and time-
consuming. In many cases, affinity reagents for novel pro-
tein candidates do not even exist and it is difficult to multi-
plex targets without creating significant interferences and 
cross-reactivity. These limitations of immunoassays have in-
centivized the development of alternative approaches. The 
recent explosion in the advancement of proteomic technol-
ogies centering on targeted MS and protein microarrays has 
provided great opportunities for researchers to use them as 
“bridging technologies” for clinical proteomic investigation 
of disease-relevant changes in tissues and biofluids. 
To address many of the critical challenges facing the pro-
tein biomarker community, the NCI launched the Clinical 
Proteomic Technologies for Cancer initiative (CPTC) in 
2006 (http://proteomics.cancer.gov). The overall goals of 
CPTC during the first 5 yr were to focus on removing sev-
eral of the major barriers in proteomics research to enable 
the accurate, efficient and reproducible identification, and 
quantification of meaningful numbers of proteins that could 
drive high value clinical biomarker qualification studies. 
Achieving this goal would provide a firm foundation for the 
field of discovery proteomics and enable the rational devel-
opment of clinical biomarkers to address various needs in 
cancer drug development, diagnostics and clinical manage-
ment.
Since its launch, CPTC has made significant progress in 
developing an accurate and quantitative biomarker assay 
workflow for proteomics, incorporating common technol-
ogy standards, standard operating procedures (SOPs), data 
analysis standards, critically needed reagents (affinity and 
reference materials), and an open access proteomics data-
base [32-37]. The new protein biomarker workflows devel-
oped by CPTC that incorporate go/no-go decision points, 
address the variability of methods and technologies–which 
enable researchers to accurately, reliably and quantitatively 
Fig. 2. The envisioned National Cancer Institute-Clinical Proteomic Technolo-
gies for Cancer initiative (NCI-CPTC) development pipeline from discovery to 
qualification. (A) The gap in the current proteomics research pipeline. (B) The 
incorporation of verification into the NCI-CPTC pipeline between discovery 
and qualification.
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identify large numbers of proteins (see below). Conse-
quently, CPTC has quickly evolved into a national (and in-
ternational) community resource that links technologists 
with cancer biologists and clinicians to accelerate the devel-
opment, improvement and standardization of proteomic 
technologies for the detection of cancer-relevant proteins/
peptides in clinical biospecimens.
NCI-CPTC incorporated an intermediate “bridging” step 
called “biomarker verification” in its pipeline to efficiently 
translate proteomic discoveries into clinical qualification 
studies (Fig. 2B). In this context, biomarker verification is 
defined as the process of credentialing prioritized “bio-
marker candidates” using analytically robust, reproducible 
and quantitative multiplex assays on statistically powered 
number of samples with clinical relevance. Credentialed 
proteins successfully passing this stage of the pipeline are 
considered verified biomarkers of high value for translating 
into large-scale clinical qualification studies.
One of the main verification technologies currently being 
tested by CPTC is based on an existing technology, Multiple 
Reaction Monitoring Mass Spectrometry (MRM-MS), 
which has been used for decades in clinical reference labo-
ratories to accurately measure small molecules in plasma, 
such as drug metabolites [38, 39]. MRM-MS has only re-
cently proven suitable for use in pre-clinical studies to rap-
idly screen and measure large numbers of candidate pro-
teins in complex patient samples necessary for biomarker 
verification [40-43]. MRM-MS provides a rapid way to 
measure the abundance of a particular candidate(s) and de-
termine whether changes in abundance correspond to the 
presence or stage of a disease. Prior to applying MRM-MS 
based assays on clinical biospecimen, precursor peptide ions 
are selected from previous experiments combining empiri-
cal MS data, database searches of peptide libraries, and soft-
ware predictions to develop the best peptide candidates to 
monitor. As illustrated in Fig. 3, the general components of 
MRM-MS based approaches for targeted protein quantita-
tion encompass three quadrupoles (QQQ) for enhanced 
sensitivity and selectivity on a triple quadrupole mass spec-
trometer. The first quadrupole (Q1) is designed to transmit 
only the selected precursor peptide ion (m/z) into the sec-
ond quadrupole (Q2) where collisionally-induced dissocia-
tion (CID) occurs to generate a signature fragment ion of 
particular m/z value or several fragment ions allowed to be 
admitted into the third quadrupole (Q3) for monitoring. 
Consequently, peptide quantitation is based on measuring 
the intensity of the product ion(s) selected from Q3. MRM-
MS can precisely detect a wide variety of peptides and pro-
teins via CID or MS/MS. When coupled with chemically 
identical heavy isotope labeled internal standard peptides of 
known amounts (stable isotope dilution mass spectrome-
try), this approach has the potential benefits for accurate 
quantitation of target peptides that make it a desirable alter-
native to immunoassays including, but not limited to, 
shorter assay development timeline, lower cost, high multi-
plexing capability, potential for high specificity, inclusion of 
internal standards, and particular advantages for PTMs, 
mutations and other variants of a protein. On the other 
hand, there are potential drawbacks of MRM-MS assays 
which may include: the complex selection process for deter-
mining target precursor peptide ions to monitor, relatively 
low resolution of QQQ-MS (usually unit resolution) in re-
solving components in complex biofluids, and the possibil-
ity of interference from in-source fragmentation of abun-
dant peptides that prevent analysis of desired precursor 
peptides. In terms of sensitivity, MRM-MS assays alone are 
at best in the range of μg per milliliter of biofluids. However, 
when coupled with immunoaffinity enrichment [i.e., Stable 
Isotope Standards and Capture by Anti-Peptide Antibodies 
(SISCAPA)] [44-46], it elevates the sensitivity of detection 
several orders of magnitude. With improvements in gener-
ating monoclonal antibodies against target signature pep-
tides, instrument designs and workflow automation, MRM-
MS may potentially provide a very reliable go/no-go deci-
sion point in the new CPTC biomarker development pipe-
line. The complement of a LC-MRM-MS assay is iMALDI 
(immuno matrix-assisted laser desorption ionization), 
where the beads with the affinity-bound peptides attached 
are placed directly on a MALDI mass spectrometer, and the 
MALDI matrix solvent elutes the peptides from the beads 
[47, 48]. The presence of the peptide, and its peak height or 
Fig. 3. Multiple Reaction Monitoring Mass Spectrometry (MRM-MS). A sche-
matic of a triple quadrupole mass spectrometer (QQQ-MS) commonly used 
in MRM-MS analysis: Q1 and Q3 represent two mass filters for precursor and 
fragment ion selection while Q2 (collision cell) creates fragment ions via col-
lisionally-induced dissociation (CID). In this case, one of the three peptide 
precursor ions (colored in blue) is selected in Q1, fragmented in Q2 and 
quantitated using one of its fragment ions (transition) selected in Q3 by the 
relative intensity of its peak area. An MRM-MS assay offers multiplexing ca-
pability of many target analytes in a single HPLC run.Boja ES, et al.  •  The Path to Clinical Proteomics Research
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peak area, are then determined from an MS spectrum for 
quantitation in the MS mode, while peptide identities are 
confirmed with CID or MS/MS. In principle, iMALDI can 
be performed with only a MALDI-MS instrument, but it 
can also be used in the “MRM mode” on an MALDI-MS/
MS mode.
2. Standardization and optimization of MRM-MS technology
To determine the reliability and transferability of this 
technology across instrument platforms and laboratories, 
the CPTC network conducted a first-of-its-kind seminal 
study to assess the reproducibility of this approach in 2009. 
CPTC data [34] shows that MRM-MS based platforms can 
consistently measure a number of candidate proteins across 
multiple laboratories sensitively and quantitatively in a high 
throughput fashion on instruments already deployed in 
clinical diagnostic laboratories. The collective results dem-
onstrated the generation of reproducible MRM-MS data 
using 11 target peptides from 7 proteins (22 in total includ-
ing their heavy isotope labeled internal standards) to con-
struct linear concentration curves without affinity enrich-
ment. The study has shown that even in the most complex 
scenario (study III) where multi-step sample preparation 
was individually performed at 8 sites, the highest CV was 
<23% using only a single transition of MRM (one fragment 
ion), except for one peptide (LEP-IND) whose CVs were 
consistently higher than others in all three studies. It is con-
ceivable that analytical variability will further decrease with 
reduced or more streamlined sample preparation. Further-
more, automation with robotics in conjunction with soft-
ware development should eventually reduce labor-intensive 
workflow, variability between different instrumentation 
platforms, and the need for high level of expertise currently 
required to perform this type of assays, while assay specific-
ity will be improved by monitoring multiple transitions for 
a single peptide and multiple peptides (an average of 3-5) 
from the same protein and highly specific antibodies. Nev-
ertheless, this inter-laboratory study represents the first 
critical step toward potential widespread implementation of 
assays for the pre-clinical verification of candidate biomark-
ers. Follow-up studies to this are ongoing which include 
targeting cancer-specific proteins, enhancing sensitivity, 
lowering the coefficients of variation (CV), increasing mul-
tiplex level, and assessing reproducibility across a larger 
network of institutions on more instrument platforms.
3. Understanding regulatory science
In addition to restructuring the biomarker development 
pipeline, it is critical to introduce regulatory science to the 
proteomics research and clinical chemistry community in 
order for this technology to be translated from the laboratory 
to the clinic. Navigating the regulatory process is daunting by 
itself, and this intensifies when new technologies are brought 
under review as the kind of proteomic technologies being 
used for biomarkers are relatively new to the US FDA, which 
creates uncertainty both on the part of researchers in how 
their findings should be presented in a submission to the 
agency, and on the part of the FDA in evaluating the data. 
In the USA, device clearance or approval rests on the abil-
ity of the sponsor to provide analytical and clinical data that 
demonstrate that the device performance is adequate to 
meet its claimed intended use [49]. In case of novel mark-
ers, simple analytical detection or quantification of an ana-
lyte is inadequate. Significance of the measurement of novel 
markers for clinical management of the patient must also be 
demonstrated, either through clinical data, or in some cases, 
through sufficient credible published information that sup-
ports clinical use. A premarket submission document in-
cludes a device intended use/indication for use, a descrip-
tion of the device covering both the instrument and re-
agents, and analytical and clinical performance studies eval-
uating performance of the device for its intended use. The 
analytical performance of the device (i.e., test or assay) is 
described in terms of precision, accuracy and performance 
around the cut-off point, along with other performance 
measurements such as specificity, sensitivity, linearity, limit 
of detection and limit of quantitation, as required for any 
assays. A detailed description of appropriate internal and 
external controls and calibrators used in the assay should 
also be included in the submission. To complicate these 
even more, laboratory-developed tests (LDTs or “home-
brew tests”) currently exist for at least 96 protein analytes 
for which there is no FDA-approved test. LDTs have histori-
cally been a general subject of FDA enforcement discretion. 
However, the FDA’s longstanding policy of enforcement dis-
cretion may undergo some major changes as witnessed by 
the FDA’s public meeting on the oversight of LDTs [50] as 
proper clinical validation of multiplex proteomics-based 
tests used in a clinical setting might be beyond the scope of 
a single laboratory. Multiplex protein-based tests will likely 
require further simplification and analytical robustness in 
order to be used extensively in clinical applications.
Multiplex protein-based assays discussed here, defined as 
device/test systems where one or more protein/peptide tar-
gets are simultaneously detected via a common process of 
sample preparation, measurement, and interpretation, are 
intrinsically very complex. If multiple results from multiple 
measurements are subsequently interpreted via an in vitro 66     www.kjlm.org
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Diagnostic Multivariate Index Assay (IVDMIA) software, 
which combines the values of multiple variables using an 
interpretation function to yield a single, patient-specific re-
sult (e.g., a classification, score, etc.) whose derivation is 
non-transparent and cannot be independently derived or 
verified by the end user, it becomes even more complicated 
for individual users to validate. A recent community-wide 
research effort extensively evaluated current practices on 
the development and validation of classifiers and composite 
scores using DNA microarray-based predictive models [51]. 
Furthermore, the FDA drafted a guidance document on 
IVDMIA devices [52]. An example of an IVDMIA using 
individually measured values of multiple proteins to derive 
a patient-specific score to help a physician evaluate the like-
lihood that an ovarian adnexal mass is malignant or benign 
prior to a planned surgery is the FDA-cleared OVA1 test 
developed by Vermillion, Inc. [53]. As the field continues to 
evolve, establishing a standardized evaluation paradigm for 
these types of complex tests involving measurements of 
multiple analytes and interpretive software should help en-
sure the highest level of performance within and across lab-
oratories in order to provide the most accurate test results 
for patients. For a multiplex protein-based assay, analytical 
validation becomes much more challenging as the FDA re-
quires that all analytes in the panel meet analytical perfor-
mance criteria rather than extrapolating the performance of 
one analyte to all others. In particular, this type of assays 
should address cross-reactivity or interference of analytes 
within and outside the panel. Having realized the impor-
tance of this aspect for the greater research community, the 
NCI-CPTC collaborates with the FDA to understand likely 
analytical evaluation requirements for diagnostic assays 
based on these multiplex protein-based technologies to en-
sure the safety and effectiveness of these tests for their in-
tended use. As a result, mock 510(k) premarket submissions 
based on targeted proteomic platforms of MRM-MS and 
multiplex immunological arrays were developed to educate 
the community on the regulatory processes in assay clear-
ance/approval by the FDA [54, 55] (Fig. 4).
In practice, there are currently multiplex MRM-MS-based 
assays being used or under development in clinical labora-
tories. Thyroglobulin, for example, a serum biomarker al-
ready used (immunoassays) in conjunction with imaging to 
determine the clinical management of patients following 
treatment of thyroid carcinoma, represents one of the best-
validated serum tumor markers in clinical chemistry [56, 
57]. However, it is also an example of a biomarker whose 
clinical utility is limited in analytical methods due to inter-
ferences from nonspecific heterophilic interfering antibod-
ies [58, 59] and thyroglobulin autoantibodies [60], etc. In 
order to circumvent these problems, an MRM-MS based as-
say in combination with immunoaffinity enrichment of 3 
tryptic peptides of thyroglobulin has been developed as a 
LDT [61]. As a result, serum thyroglobulin was quantified 
based on the 3 endogenous peptide using LC-MRM-MS 
with external calibrators after extracting them from tryptic 
digests of human serum using polyclonal antibodies raised 
against them. It has been demonstrated that this approach 
has the ability to detect tryptic peptides of thyroglobulin at 
picomolar concentrations, while digesting the endogenous 
immunoglobulins that can potentially interfere with tradi-
tional immunoassays.
To meet FDA’s requirements for analytical validation us-
ing multiplex MRM-MS technologies, three critical compo-
nents of the assay configured for targeted analytes in the 
context of their intended use should be considered: (1) 
sample preparation leading to final analysis on a MS plat-
form; (2) the instrument platform itself (i.e., QQQ-MS); (3) 
software (instrument control and result analysis). Firstly, 
sample preparation should address the need to include con-
trols for assessing the efficiency and variability of proteolytic 
digestion of proteins in different samples because evidence 
for trypsin digestion variability in proteomic analysis exists 
and needs to be addressed [62]; and/or gauging analytical 
recovery of immunoaffinity-enriched proteins and PTMs 
during sample preparation [63] prior to being considered 
for use in the clinical setting. It is the reproducibility of the 
“overall measured protein concentration” calculated from 
target proteolytic peptides derived from the same protein 
Fig. 4. Regulatory science education through the development of public 
documents that enable a more efficient flow through biomarker discovery, 
development and regulatory processes.
-How to submit a multiplex protein-based assay for US FDA clearance/approval?
-What sort of questions will the FDA ask about multiplex protein-based assays?
-How does one address 
complexity of analytically  
validating multiple protein/ 
peptide targets on a multiplex 
platform such as MRM-MS 
and protein arrays?
-How does one design a 
study that ensures the  
safety of multiplex  
protein-based assays  
for patients?Boja ES, et al.  •  The Path to Clinical Proteomics Research
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that would need to be shown consistent from run to run. If 
one of the peptide measurements appears consistently as an 
outlier, assay developers need to understand why this oc-
curred, what effect it would have on the assay, and whether 
the outlier and its effect would be recognized by the assay 
quality control (QC) system since an outlier could signal 
the presence of PTMs, or interferences from other proteins 
and single nucleotide polymorphisms (SNPs), etc. 
Secondly, although MS for clinical use, as previously de-
scribed under 21 CFR 862.2860, are considered Class I de-
vice (low risk usually requiring only general controls) and 
exempt from 510(k) process [64], FDA regulations differen-
tiate between those MS instrumentation and more complex 
instrumentation such as those instruments that include in-
terpretive software and complex measurement functions, 
which may be regulated similarly to the multiplex instru-
mentation for nucleic acid assays (Class II). Moreover, in-
strumentation used to run a specific assay takes on the clas-
sification of that assay when submitted for that particular in-
tended use. For instance, a Class II assay based on MS analy-
sis would involve evaluation of that MS as a part of a Class II 
assay for that intended use. Although basic operating princi-
ples are the same, modern instrument design from different 
manufacturers and interfaced HPLC systems (nano-scale vs. 
micro-scale flow rates, chip vs. non-chip-based) could be 
different, potentially causing non-equivalent performance of 
assays on different instruments, and thus requiring different 
specifications for each instrument. In light of this, the NCI-
CPTC network conducted an interlaboratory study, as pre-
viously described, which showed promise in obtaining re-
producible MRM-MS data across instrument platforms and 
laboratories [32]. Once analytical performance would be 
demonstrated as equivalent on different MS platforms, sepa-
rate regulatory evaluations of the same analyte(s) on each 
instrument may become simplified or unnecessary. For 
FDA submission, if performance on a specific MS instru-
ment/platform as a part of a diagnostic assay is adequate, it 
generally leads to an approval of an assay only on that spe-
cific instrument used in evaluating performance. This can 
be followed by subsequent submissions addressing any 
modifications to the assay, such as addition of another in-
strument platform. For example, the most commonly used 
QQQ-MS could be cleared as a part of an MRM-MS assay 
by measuring a protein analyte with relatively low-risk in-
tended use, which would make this instrument manufac-
tured under quality system (Good Manufacturing Practice 
[GMP]) available for clinical laboratory testing, and can be 
followed by addition of other QQQ-MS manufacturers on 
the same analyte. The evaluation of instrument platform, 
however, should include all necessary components and ac-
cessories (e.g., HPLC columns and tubings, electrospray 
source, software). Any changes to this cleared platform 
would be re-evaluated by the assay manufacturer, and may 
or may not need subsequent regulatory submissions to ad-
dress the safety and effectiveness of the changed platform. 
Additional analytes or kits can subsequently be cleared for 
use on the same platform without additional platform-spe-
cific information, other than assay-specific components of 
the instrumentation.
Finally, pre-defining certain parameters in software pack-
ages on instruments (e.g., MS) and manufacturing instru-
ments under GMP guidelines should reduce operator-spe-
cific bias, requirements for extensive specialized training 
and analytical variability at the platform level. If interpretive 
IVDMIA software to reach a patient-specific result from 
multiple measurements is used, the FDA generally requires 
that software algorithms included in the assay for data and 
results interpretation be pre-specified before analyzing 
study data. Alteration of the algorithm to better fit the data 
after the study is performed is generally unacceptable [54].
4. Important role of clinical laboratories
Clinical chemists undoubtedly play a huge role in the an-
alytical validation of diagnostic tests and are thus required 
to routinely verify (confirm) previously cleared/approved 
tests by the regulatory agency in their facilities. Post-market 
analytical validation is routinely performed by clinical 
chemists as the QC process to evaluate whether or not a 
previously cleared test (instrument, controls, reagents, etc.) 
complies with regulations, specifications, or conditions. 
These QC studies typically involve precision, accuracy, lin-
earity and lower limit of detection and quantitation. When 
clinical chemists set up a method for an approved multiplex 
protein assay using a patient-specific “score”, they should 
consider how to perform studies to validate the score. One 
approach may involve running adequate number of positive 
and negative patients to assess the performance of such a 
“score” in their diagnosis when compared to their medical 
charts and final clinical diagnosis. In the USA, even though 
clinical labs are not necessarily responsible for clinical vali-
dation of tests, the lab director should consider clinical va-
lidity when selecting a test for patients.
Additionally, international collaborative efforts provide 
an effective means to educate key clinical laboratory audi-
ences on the need for and use of common technologies and 
standards in proteomic workflows and to share knowledge 
and experience on commonly interesting targets, assays and 
new technologies.68     www.kjlm.org
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5. Reference documents by clinical laboratory standards    
     institutes 
Clinical Laboratory Standards Institutes (CLSI) docu-
ments are useful to assay sponsors and the regulatory agency 
in the process of preparing and reviewing premarket sub-
missions, and are highly regarded by other organizations of 
clinical professionals. CLSI aims to develop global consen-
sus standards and guidelines for healthcare testing (industry, 
government, and professional) [65]. A CLSI document goes 
through rounds of rigorous review prior to publication. 
These documents are developed and approved by consensus 
of stakeholders in particular areas, which may include FDA 
representatives, and go through a public comment phase. 
The FDA can either fully or partially recognize CLSI docu-
ments as standards, and compliance with the recommenda-
tions of CLSI documents may be accepted as evidence of 
fulfillment of certain FDA analytical requirements. EP-17A, 
Vol. 24, No. 34, Protocols for Determination of Limits of 
Detection and Limits of Quantitation; Approved Guideline, 
for example, is a commonly referenced document for ana-
lytical performance of a test. While CLSI documents on 
multiplex proteomics assays currently do not exist, general 
guidance could be drawn from the nucleic acid-based mul-
tiplex world. An example of that is MM-17A (Verification 
and Validation of Multiplex Nucleic Acid Assays; Approved 
Guideline).
6. Future perspective: integrating genomics with      
     proteomics (systems biology)
The mapping of the human genome represents a true 
milestone in medicine and has led to an explosion in dis-
coveries and translative research in life sciences. Indeed, 
this important knowledge base has enabled rapid develop-
ment in the areas of diagnostics, gene therapy, new drug 
targets discovery, and personalized therapies [66, 67]. The 
expansion of biological knowledge through the Human Ge-
nome Project (HGP) has also been accompanied by the de-
velopment of new high throughput techniques, providing 
extensive capabilities for the analysis of a large number of 
genes or the whole genome, for example, the development 
of multiplex cytogenetic arrays for the detection of copy 
number variations (CNVs) and SNPs. The completion of 
the human genome, however, has presented a new and even 
more challenging task for scientists: the characterization of 
the human proteome. Unlike the genome project, there are 
major challenges in defining a comprehensive Human Pro-
teome Project (HPP) due to (1) potentially very large num-
ber of proteins with PTMs, mutations, splice variants, etc.; 
(2) the diversity of technology platforms involved; (3) the 
variety of overlapping biological “units” into which the pro-
teome might be divided for organized conquest; and (4) 
sensitivity limitations in detecting proteins present in low 
abundances.
The ultimate goal for translational medicine is to be able 
to perform assays in various clinical samples at multiple lev-
els: DNA (genome), RNA (transcriptome) and protein (pro-
teome) using the knowledge and technologies coming out of 
these large-scale projects correlative to a specific phenotype. 
Currently, large-scale multidisciplinary team science based 
initiatives, such as The Cancer Genome Atlas (TCGA) and 
The International Cancer Genome Consortium (ICGC), are 
characterizing diseased cancer genomes of tumor tissues to 
understand different cancers at a genetic level. As a result, 
genetic alterations associated with cancers including copy 
number aberration, mutation, microdeletion and others 
have been generated by multidimensional data sets and high 
level integrative analysis [68, 69]. This information now pro-
vides a genetic basis and a great opportunity for the com-
munity to characterize and quantify proteins (reflecting ge-
netic alterations if detectable) and their alterations and 
PTMs in the cell. The resulting proteomic evidence will cor-
roborate or complement the genetic aberrations detected in 
these tumors, providing deeper understanding of cancer 
and other diseases in the context of biology and clinical util-
ity. For instance, the integrative analysis of DNA copy num-
ber, gene expression and DNA methylation aberrations in 
206 glioblastomas (GBM), the most common form of adult 
brain cancer, as characterized by the TCGA, revealed the 
roles of ERBB2, NF1 and TP53, and frequent mutations of 
the phosphatidylinositol-3-OH kinase regulatory subunit 
gene PIK3R1, as well as providing a network view of the 
pathways altered in the development of glioblastoma [70]. 
In addition, integration of mutation, DNA methylation and 
clinical treatment data showed a link between O
6-methyl-
guanine-DNA methyltransferase (MGMT) promoter meth-
ylation and a hypermutator phenotype consequent to mis-
match repair deficiency in treated glioblastomas, an obser-
vation with potential clinical implications. Another study 
performed by the TCGA network described a robust gene 
expression-based molecular classification of GBM into Pro-
neural, Neural, Classical, and Mesenchymal subtypes as de-
fined by aberrations and gene expression of EGFR (Classi-
cal), NF1 (Mesenchymal), and PDGFRA/IDH1 (Proneural) 
[71]. Interestingly, response to aggressive therapy differs by 
subtype, with the greatest benefit in the Classical subtype 
and no benefit in the Proneural subtype. This finding poten-
tially provides a framework that unifies transcriptomic and 
genomic dimensions for GBM molecular stratification, and Boja ES, et al.  •  The Path to Clinical Proteomics Research
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if corroborated at the protein level, it would vastly expand 
our knowledge on GBM and ultimately improve the clinical 
practice of medicine for GBM patients. By leveraging the 
advances in reproducibility and transferability of clinical 
proteomic platforms from the first 4.5 yr of the NCI-CPTC 
initiative to genomic evidence provided by TCGA and 
ICGC, for example, will provide a rational pathway for ana-
lytically verified biomarker candidates (Fig. 5). In this envi-
sioned route, high throughput proteomics will analyze sta-
tistically-powered unbiased biospecimens (tissues, proximal 
fluids, and blood) to identify and quantify proteins as the 
power of statistics in biomarker research has long been ig-
nored, contributing to the failure of qualifying new protein 
biomarkers by the FDA at a reasonable rate. The integration 
and interrogation of the proteomic and genomic data will 
provide potential biomarker candidates which will be priori-
tized for downstream targeted proteomic analysis. These 
biomarker targets will be used to create multiplex, quantita-
tive assays for verification and prescreening to test the rele-
vance of the targets in clinically relevant and unbiased sam-
ples. The outcomes from this approach will provide the 
community with verified biomarkers which could be used 
for clinical qualification studies; high quality and publicly 
accessible datasets; and analytically validated, multiplex, 
quantitative protein/peptide assays and their associated high 
quality reagents for the research and clinical community.
Beyond the integration of “-omics” data and information, 
future proteomic endeavors should continue to support 
technology development, optimization and standardization. 
Incorporation of the most up-to-date and efficient technol-
ogies is critical in successfully propelling the translation of 
proteomic findings into clinically relevant biomarkers. 
Meanwhile, rigorous assessment of biospecimen and data 
quality through quality assessment (QA)/QC criteria at 
each step of the biomarker development pipeline should 
continue to be supported to make “go” or “no-go” decisions. 
These efforts, combined with continued collaborations with 
regulatory agencies and clinical chemists, will expedite the 
development of individualized patient care through clinical 
proteomics.
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